# A Study to Assess the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 in Adults With Locally Advanced or Metastatic Solid Tumours

> **NCT07213817** · PHASE1,PHASE2 · RECRUITING · sponsor: **Ipsen** · enrollment: 114 (estimated)

## Conditions studied

- Locally Advanced Solid Tumor
- Metastatic Solid Tumor

## Interventions

- **BIOLOGICAL:** IPN60300

## Key facts

- **NCT ID:** NCT07213817
- **Lead sponsor:** Ipsen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-05
- **Primary completion:** 2028-10-30
- **Final completion:** 2028-10-30
- **Target enrollment:** 114 (ESTIMATED)
- **Last updated:** 2026-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07213817

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07213817, "A Study to Assess the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 in Adults With Locally Advanced or Metastatic Solid Tumours". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07213817. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*